Background. Aducanumab, a new monoclonal antibody that targets β-amyloid aggregates, has been granted conditional approval by the U.S. FDA for treatment of mild Alzheimers disease (AD). The approval of this drug without a confirmed significant clinical impact has resulted in several debates. Objective. In this narrative review, aducanumab approval-related controversy, the drugs pharmacokinetics and pharmacodynamic characteristics, evidence from the efficacy and safety trials of aducanumab, implications of the drug approval, and the future directions in the management of patients with AD are summarized. Methods. Using relevant keywords, Google Scholar, Web of Science, and MEDLINE databases and manufacturers website were searched. Results. Infusion of aducanumab at a higher dose resulted in a modest slowing of cognitive decline among patients with mild cognitive impairment or early-onset AD dementia. The drug however can cause amyloid-related imaging abnormalities. Due to modest impact on cognition, the use of this drug by patients with AD will most likely be limited. The manufacturer is required to run an extended phase IIIb trial to verify the benefit of this drug. Access to therapy requires a careful selection of patients and periodic monitoring to ensure the optimal use of the drug. Conclusion. Despite the limitations, aducanumab is the first disease-modifying therapy approved for the treatment of AD. Aducanumab addresses a part of the pathogenesis of AD; therefore, drugs that can act on multiple targets are needed. In addition, the search for preventive strategies, validated plasma-based assays, and newer drugs for AD, which are effective, safe, convenient, and affordable, is vital.
1 January 2024 in International Journal of Alzheimer's Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder caused by the accumulation of amyloid‐beta (Aβ) proteins and neurofibrillary tangles in the brain. There have been recent advancements in antiamyloid therapy for AD. This narrative review explores the recent advancements and challenges in antiamyloid therapy. In addition, a summary of evidence from antiamyloid therapy trials is presented with a focus on lecanemab. Lecanemab is the most recently approved monoclonal antibody that targets Aβ protofibrils for the treatment of patients with early AD and mild cognitive impairment (MCI). Lecanemab was the first drug shown to slow cognitive decline in patients with MCI or early onset AD dementia when administered as an infusion once every two weeks. In the Clarity AD trial, lecanemab was associated with infusion‐site reactions (26.4%) and amyloid‐related imaging abnormalities (12.6%). The clinical relevance and long‐term side effects of lecanemab require further longitudinal observation. However, several challenges must be addressed before the drug can be routinely used in clinical practice. The drug’s route of administration, need for imaging and genetic testing, affordability, accessibility, infrastructure, and potential for serious side effects are some of these challenges. Lecanemab’s approval has fueled interest in the potential of other antiamyloid therapies, such as donanemab. Future research must focus on developing strategies to prevent AD; identify easy‐to‐use validated plasma‐based assays; and discover newer user‐friendly, and cost‐effective drugs that target multiple pathways in AD pathology.
3 September 2024 in CNS Neuroscience & Therapeutics
Aims: The study aimed to evaluate the potential benefits of luteolin treatment in Huntington's disease (HD), an inherited progressive neurodegenerative disorder.Methods: HD N171‐82Q transgenic and WT mice received luteolin or vehicle for treatment at 6 weeks of age. The mice's body weight changes and survival rates were monitored throughout the study, and a series of motor functional tests were conducted. Serum level of the marker NfL was also determined. Immunohistochemical staining and western blotting were utilized to assess the expression of huntingtin aggregates.Results: Luteolin treatment enhanced survival and prevented weight loss in HD mice compared to the vehicle‐treated HD group. Furthermore, the luteolin‐treated HD mice exhibited enhanced motor coordination and balance and significantly reduced motor dysfunction. Also, luteolin decreased serum NfL levels in HD mice. Notably, the accumulation of huntingtin aggregates was significantly reduced in the brain's cortex, hippocampus, and striatum of luteolin‐treated HD mice compared to the vehicle‐treated HD group.Conclusion: Luteolin holds promise as a therapeutic agent for improving survival outcomes, managing motor dysfunction, and reducing huntingtin aggregates in HD. The findings are of significance as currently, there are no approved therapeutic interventions that reverse HD pathology or slow down its progression.
Background: Phenytoin is a commonly used sedative antiepileptic medication in many countries. It is used against tonic-clonic and complex partial seizures. Phenytoin is reported to cause a range of deleterious and erratic side effects at therapeutic and toxic doses. Case report: An eighteen year old female presented with ataxia, nystagmus, gingival hypertrophy, nodular skin lesions and hirsutism while she was on treatment with oral phenytoin at 200 mg once daily since the past five years for seizures. Based on the presenting signs and symptoms, her condition was diagnosed as phenytoin induced toxicity. The symptoms improved significantly after the offending drug was withdrawn. Alternatively she was started on oral carbamazepine. Naranjo and WHO causality assessment was done, indicating a probable relationship between the patient’s symptoms and her use of phenytoin. Conclusion: This case report and review highlights the adverse drug reactions of phenytoin and the need of regular monitoring in patients on long term therapy. Key words: Ataxia, Gingival hypertrophy, Hirsutism, Nodular skin lesions, Nystagmus Phenytoin toxicity.
Antimicrobial selection, prescribing, and resistance are global health issues resulting from the overuse and misuse of antimicrobials in the healthcare and
1 January 2016 in International Journal of Research in Medical Sciences
Background: Type-2 diabetes complications contribute to increased morbidity and mortality and hence early diagnosis and control of diabetes is necessary. Adenosine deaminase activity is present in almost all human tissues, but the highest levels are found in lymphoid system. Aim of the study was to identify the correlation between adenosine deaminase levels and insulin resistance in type-2 diabetics and serum adenosine deaminase levels and glycemic control. Methods: In this case control study, patients with type-2 diabetes mellitus, attending out-patient department or admitted in the hospital during the study period, fulfilling the study criteria were taken up. Results: 200 patients were included in the study, with 100 patients in the case and controls group respectively. The mean body mass index, waist circumference, fasting blood sugar, post prandial blood sugar, glycosylated hemoglobin, fasting serum insulin levels, quantitative insulin sensitivity check index values were found to be significantly elevated (p Conclusions: We identified that the highest Adenosine deaminase levels were detected in poorly controlled type-2 diabetes mellitus. Adenosine deaminase levels were found to have positive correlation with body mass index, fasting blood sugar and post prandial blood sugar levels. Adenosine deaminase levels were also positively correlated with insulin resistance, as calculated by homeostasis model assessment of insulin resistance. Adenosine deaminase levels were found to have an inversely proportional correlation with quantitative insulin sensitivity check index.Key words: Adenosine deaminase, Diabetes mellitus, HOMA-INR, Insulin resistance, Insulin sensitivity, QUICKI